SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...

SAN DIEGO--(BUSINESS WIRE)--With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s ...

The Food and Drug Administration says Abbott's BinaxNOW test and Quidel's QuickVue can be sold without a prescription. FDA Authorizes 2 Rapid, At-Home Coronavirus Tests Imagine waking up, brushing ...

SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of ...

QuidelOrtho Corporation recently expanded its QUICKVUE portfolio with the launch of the QUICKVUE Influenza + SARS Test, a rapid, CLIA-waived immunoassay for professional use that delivers simultaneous ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Rapid tests for the H1N1 pandemic flu are at least 89% accurate ...

Says can add 2009 H1N1 influenza A virus reactivity info Shares rise 6 percent in pre-market trade Sept 17 (Reuters) - Quidel Corp , a provider of rapid diagnostic tests, said it received special ...

NEW YORK (CBS.MARKETWATCH) -- Shares of diagnostic test-maker Quidel were sharply higher in afternoon trade after Pacific Growth started coverage of the stock with an "overweight" rating. Analyst Adam ...

Quidel Corporation QDEL has been gaining on the back of its strong diagnostics portfolio. A solid third-quarter 2021 performance, along with solid potential in In-Vitro Diagnostics (“IVD”) products, ...

QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician ...